The full content of Annals is available to subscribers

Subscribe/Learn More  >
Editorials |

Cardiovascular Consequences of Recombinant DNA Technology: Interleukin-2

Jeffrey M. Isner, MD; and William A. Dietz, MD
[+] Article, Author, and Disclosure Information

Grant Support: Supported in part by grants HL 32747 and HL 40518 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland.

Requests for Reprints: Jeffrey M. Isner, MD, St. Elizabeth's Hospital, 736 Cambridge Street, Boston, MA 02135.

St. Elizabeth's Hospital and Tufts School of Medicine
Boston, Massachusetts

Ann Intern Med. 1988;109(12):933-935. doi:10.7326/0003-4819-109-12-933
Text Size: A A A
This excerpt has been provided in the absence of an abstract.

In large part, the heart has profited from advances in recombinant DNA technology. The introduction of tissue plasminogen activator, for example, has been widely regarded as a major therapeutic breakthrough in the treatment of acute myocardial infarction; nearly routine use of this agent in appropriate individuals is anticipated to reduce infarct size and thereby improve residual ventricular function and survival (1). Subsequent development of similar agents with improved clot-specific lytic activity is expected to further reduce systemic toxicity so that the reduced risk-benefit ratio associated with such drug use could allow its use on an even more widespread basis.



First Page Preview

View Large
First page PDF preview





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.